Stock·NASDAQ·Healthcare
Amgen Inc. (AMGN)
- Market cap
- $234.65B
- P/E
- 25.64
- Dividend yield
- 2.30%
- Street target
- $405.00median of 34 analysts
- 52-week range
- $288.00 $447.03
The short version
Where AMGN stands today, in four lines, and what CleaRank Financial AI makes of it.
AMGN at a glance
Amgen Inc. (AMGN): Hold, 57/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($415.02 and $368.90).
- Earnings AMGN beat estimates in 8 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $30.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 25.6 against 31.9 for the Healthcare sector: broadly in line with peers (-20%).
Figures as of October 16, 2026.
CleaRank Financial AI
Amgen Inc. (AMGN) is trading at $432.79, above its 50-day and 200-day moving averages ($415.02 and $368.90), indicating positive short-to-medium term momentum.
The company has demonstrated consistent earnings beats, with the most recent quarter exceeding estimates by 11.92% and resulting in a 4.57% stock price increase. Despite this strong operational performance and a healthy profit margin of 22.95%, the stock's valuation appears stretched relative to its sector peers, trading at a P/E of 25.64 compared to the sector median of 31.9, but a higher Price-to-Sales ratio of 6.16 versus the sector median of 3.4. However, a significant concern arises from insider activity, which shows net selling totaling $30.4 million, signaling a moderate sell signal from management. Also, the median Wall Street price target of $405.00 sits below the current trading price, suggesting limited upside potential according to analysts. While the company exhibits strong return on equity at 91.47%, the combination of insider selling and analyst price targets implies caution is warranted for new entries.
Only on CleaRank
Figures we compute ourselves from AMGN's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $432.79 is 4.3% above the 50-day simple moving average of $415.02.Price above its 200-day average ›
The price is 17.3% above the 200-day simple moving average of $368.90.50-day average above the 200-day ›
The 50-day average ($415.02) is 12.5% above the 200-day average ($368.90), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 91% of its 52-week range, between $288.00 and $447.03.
AMGN share price
Pick a period: each tab shows how far AMGN has moved over it, to the last close.
Today's trading
Where AMGN sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 25.64 is 19.6% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 6.16 is 81.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $8.7B on revenue of $38.1B, a net margin of 23.0%.Beat estimates in most recent reports ›
AMGN beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.30%, or $9.94 a share a year.
Key statistics
The headline figures for AMGN.
As of October 16, 2026, AMGN trades at $432.79, with a market value of $234.65B, a P/E ratio of 25.64 and a dividend yield of 2.30%.
What the numbers say
CleaRank Financial AI's reading of AMGN's valuation, growth and risks.
Amgen Inc. (AMGN) presents a mixed fundamental picture, trading at a P/E ratio of 25.64, which is below the sector median of 31.9, but its Price-to-Sales ratio stands at 6.16, significantly higher than the sector median of 3.4.
This suggests investors are paying a premium for Amgen's sales compared to its peers. The company boasts an exceptional return on equity of 91.47% and a strong profit margin of 22.95%, indicating efficient operations and profitability. The forward revenue growth estimate for the next year is projected at 4.00%, which is below the sector average of 8.1%. This slower growth outlook, combined with a higher price-to-sales ratio, raises questions about the stock's current valuation despite its strong profitability.
AMGN against the Healthcare sector
How AMGN compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-20% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 5, 2025, AMGN has gained 55.0% against a gain of 28.3% for XLV.
Performance against XLV
AMGN and the Healthcare sector fund over the same days.
Revenue and earnings
How much AMGN sells, and how much of it becomes profit.
Revenue growth: Revenue grew 10.0% in FY2025 to $36.8B, from $33.4B a year earlier.
Profit margin: The net margin was 21.0% in FY2025, up from 12.2% the year before.
Profitable: AMGN earned $7.7B in FY2025.
Earnings reality check
Did AMGN beat what analysts expected, and how did the stock react?
Earnings record: AMGN beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $5.62 | $6.29 | +11.92% | +4.57% | +6.23% |
| Apr 30, 2026after close | $4.77 | $5.15 | +7.97% | -4.75% | -4.96% |
| Feb 3, 2026after close | $4.73 | $5.29 | +11.84% | +8.15% | +7.70% |
| Nov 4, 2025after close | $5.01 | $5.64 | +12.57% | +7.81% | +14.07% |
| Aug 5, 2025after close | $5.28 | $6.02 | +14.02% | -5.14% | -5.03% |
| May 1, 2025after close | $4.26 | $4.90 | +15.02% | -0.90% | -4.13% |
| Feb 4, 2025after close | $5.08 | $5.31 | +4.53% | +6.50% | +2.64% |
| Oct 30, 2024after close | $5.11 | $5.58 | +9.20% | +1.46% | +1.98% |
As of October 16, 2026, AMGN has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 4, 2026, came in 11.92% above the estimate and the stock moved +4.57% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 62.7, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 62.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of AMGN
The score, the reasoning behind it, and what could move the price next.
Amgen Inc. (AMGN) exhibits bullish momentum with its 14-day RSI at 62.7, indicating it is approaching overbought territory but still within a strong trend.
The stock is trading above its 20-day EMA ($414.90), 50-day SMA ($415.02), and 200-day SMA ($368.90), reinforcing the current uptrend. The MACD indicator at 5.42 also suggests positive momentum, though its magnitude should be considered in context with the stock's price. Key support levels are established around the 50-day SMA at $415.02, with resistance potentially forming near recent highs. The overall chart structure suggests continued strength in the near term, but traders should monitor for any signs of reversal if the stock fails to break through resistance or falls below its key moving averages.
Consistent Earnings Beats ›
Amgen Inc. has exceeded EPS estimates in its last four reported quarters, including an 11.92% beat in the most recent quarter, driving positive stock performance.
Source: Company Earnings ReportsSlower Projected Revenue Growth ›
Amgen Inc.'s projected revenue growth of 4.00% for the next year is below the sector average of 8.1%, which could limit future stock appreciation.
Source: Wall Street Revenue Estimates
Insider Net Selling ›
Insiders have sold a net of $30.4 million in Amgen Inc. stock across recent filings, indicating a moderate sell signal from management.
Source: Insider Transaction FilingsAnalyst Price Targets Below Current Price ›
The median Wall Street price target for Amgen Inc. is $405.00, which is below the current trading price of $432.79, suggesting limited analyst conviction for further upside.
Source: Wall Street Analyst Reports
- Amgen Inc. (AMGN) offers a dividend yield of approximately 2.30%, providing a modest income stream for investors.
Technical indicators
Momentum and trend for AMGN, from its daily closes.
As of October 16, 2026, with AMGN at $432.79, its 14-day RSI is 62.7 (showing bullish momentum without being overbought), its 50-day simple moving average is $415.02 and its 200-day is $368.90.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What AMGN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, AMGN's 1-year correlation of daily returns is +0.26 with S&P 500 (SPY), +0.16 with Nasdaq 100 (QQQ), +0.09 with Bitcoin (BTC) and +0.13 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
0/3Most analysts rate it a buy ›
12 of 34 analysts rate it a buy or strong buy, 17 a hold and 5 a sell.Median target above the price ›
The median 12-month target of $405.00 is 6.4% below the price.More buy ratings than three months ago ›
12 of 34 rate it a buy now, against 14 of 34 three months ago.
AMGN Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | UBS | Maintains | Buy |
| Oct 8, 2026 | RBC Capital | Maintains | Outperform |
| Oct 8, 2026 | Cantor Fitzgerald | Maintains | Neutral |
| Oct 7, 2026 | Truist Securities | Maintains | Hold |
| Oct 7, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Sep 29, 2026 | Scotiabank | Maintains | Sector Outperform |
As of October 16, 2026, 34 Wall Street analysts cover AMGN: 12 rate it a buy or strong buy, 17 a hold and 5 a sell or strong sell. Their 12-month price targets range from $225.00 to $500.00, with a median of $405.00, 6.4% below the price of $432.79.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
AMGN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from AMGN's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much AMGN tends to move, against the market and on its own.
The long record
AMGN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 2.53% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 24.5%, from December 2019 to March 2020, regained by May 2020.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $35,920, against $42,525 in the S&P 500 (SPY).
AMGN Drawdowns & Recovery
As of October 16, 2026, AMGN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -24.5% (December 2019 to March 2020); it regained that peak by May 2020, 2 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into AMGN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: AMGN trailed the S&P 500 over this period: $35,920 against $42,525.
A $10,000 investment in AMGN in October 2016 would be worth about $35,920 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to AMGN, and which have not.
Strongest month, January: an average of +4.85%, up in 8 of 10 years.
Weakest month, March: an average of -1.42%, up in 4 of 10 years.
This month, October: has averaged -0.40%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, AMGN's strongest calendar month has been January (average +4.85%, up in 8 of 10 years) and its weakest March (average -1.42%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in AMGN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AMGN today could grow to about $21,310 by 2036 in the base case, with a 90th-percentile outcome near $59,416 and a 10th-percentile outcome around $7,643. The simulation models price only; at today's 2.30% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
AMGN Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $586 for AMGN by 2030 in the base case, from $433 today (1.4x over 4 years). The 10th-percentile path ends near $306. These are outcomes of a Monte Carlo simulation run on AMGN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $338 | $467 | $646 | |
| 2028 | $318 | $503 | $796 | |
| 2029 | $310 | $543 | $952 | |
| 2030 | $306 | $586 | $1,120 | |
| 2031 | $306 | $632 | $1,305 |
Method: a lognormal simulation of AMGN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
AMGN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought AMGN shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, AMGN insiders reported 12 open-market sales worth $30.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Rachna Khosla
Officer
|
Sell | 3.3K | $1.3M |
| Aug 13, 2026 | Rachna Khosla
Officer
|
Option | 1.3K | $203.6K |
| Aug 7, 2026 | Matthew C. Busch
Officer
|
Grant | 730 | - |
| Aug 7, 2026 | Michael V Drake
Director
|
Grant | 63 | - |
| Aug 7, 2026 | Charles M Holley Jr
Director
|
Grant | 103 | - |
| Aug 7, 2026 | Omar Syed Ishrak
Director
|
Grant | 85 | - |
| Aug 6, 2026 | Derek Miller
Officer
|
Sell | 3.9K | $1.6M |
| Aug 6, 2026 | Nancy A Grygiel
Officer
|
Sell | 3.0K | $1.2M |
| Aug 6, 2026 | Nancy A Grygiel
Officer
|
Option | 3.0K | $526.9K |
| Aug 6, 2026 | Derek Miller
Officer
|
Option | 3.9K | $659.6K |
| May 19, 2026 | Wanda M Austin
Director
|
Grant | 665 | - |
| May 19, 2026 | Michael V Drake
Director
|
Grant | 665 | - |
| May 19, 2026 | Brian J Druker
Director
|
Grant | 665 | - |
| May 19, 2026 | Robert Andrew Eckert
Director
|
Grant | 665 | - |
| May 19, 2026 | Gregory C. Garland
Director
|
Grant | 665 | - |
| May 19, 2026 | Charles M Holley Jr
Director
|
Grant | 665 | - |
| May 19, 2026 | Omar Syed Ishrak
Director
|
Grant | 665 | - |
| May 19, 2026 | Tyler Jacks
Director
|
Grant | 665 | - |
| May 19, 2026 | Mary E Klotman
Director
|
Grant | 665 | - |
| May 19, 2026 | Ellen Jamison Kullman
Director
|
Grant | 665 | - |
| May 19, 2026 | Amy E Miles
Director
|
Grant | 665 | - |
| May 5, 2026 | James E. Bradner
Officer
|
Grant | 3.3K | - |
| May 5, 2026 | Robert A Bradway
Chief Executive Officer
|
Grant | 12.1K | - |
| May 5, 2026 | Matthew C. Busch
Officer
|
Grant | 455 | - |
| May 5, 2026 | Michael V Drake
Director
|
Grant | 79 | - |
| May 5, 2026 | Murdo Gordon
Officer
|
Grant | 3.6K | - |
| May 5, 2026 | Jonathan P Graham
General Counsel
|
Grant | 2.6K | - |
| May 5, 2026 | Peter H. Griffith
Chief Financial Officer
|
Grant | 3.6K | - |
| May 5, 2026 | Nancy A Grygiel
Officer
|
Grant | 485 | - |
| May 5, 2026 | Charles M Holley Jr
Director
|
Grant | 128 | - |
| May 5, 2026 | Omar Syed Ishrak
Director
|
Grant | 106 | - |
| May 5, 2026 | Rachna Khosla
Officer
|
Grant | 500 | - |
| May 5, 2026 | Derek Miller
Officer
|
Grant | 910 | - |
| May 5, 2026 | David M. Reese
Chief Technology Officer
|
Grant | 2.9K | - |
| May 5, 2026 | Esteban Santos
Officer
|
Grant | 2.7K | - |
| May 4, 2026 | Nancy A Grygiel
Officer
|
Sell | 1.2K | $400.5K |
| Mar 4, 2026 | Robert A Bradway
Chief Executive Officer
|
Option | 119.8K | $18.7M |
| Mar 3, 2026 | Robert A Bradway
Chief Executive Officer
|
Grant | 42.7K | - |
| Mar 3, 2026 | Matthew C. Busch
Officer
|
Grant | 938 | - |
| Mar 3, 2026 | Murdo Gordon
Officer
|
Grant | 13.4K | - |
| Mar 3, 2026 | Jonathan P Graham
General Counsel
|
Grant | 10.7K | - |
| Mar 3, 2026 | Peter H. Griffith
Chief Financial Officer
|
Grant | 12.1K | - |
| Mar 3, 2026 | Nancy A Grygiel
Officer
|
Grant | 2.0K | - |
| Mar 3, 2026 | Rachna Khosla
Officer
|
Grant | 1.9K | - |
| Mar 3, 2026 | Derek Miller
Officer
|
Grant | 3.5K | - |
| Mar 3, 2026 | David M. Reese
Chief Technology Officer
|
Grant | 12.1K | - |
| Mar 3, 2026 | Esteban Santos
Officer
|
Grant | 11.3K | - |
| Feb 26, 2026 | Esteban Santos
Officer
|
Sell | 54.8K | $20.8M |
| Feb 26, 2026 | Esteban Santos
Officer
|
Option | 54.8K | $9.3M |
| Feb 19, 2026 | Matthew C. Busch
Officer
|
Sell | 1.0K | $375.8K |
| Nov 20, 2025 | Nancy A Grygiel
Officer
|
Sell | 3.1K | $1.1M |
| Nov 20, 2025 | Nancy A Grygiel
Officer
|
Option | 3.1K | $532.7K |
| Nov 12, 2025 | Murdo Gordon
Officer
|
Sell | 6.9K | $2.3M |
| Nov 12, 2025 | Rachna Khosla
Officer
|
Sell | 890 | $299.3K |
| Nov 12, 2025 | David M. Reese
Chief Technology Officer
|
Grant | 6.8K | - |
| Nov 7, 2025 | Michael V Drake
Director
|
Grant | 218 | - |
| Nov 7, 2025 | Charles M Holley Jr
Director
|
Grant | 265 | - |
| Nov 7, 2025 | Omar Syed Ishrak
Director
|
Grant | 218 | - |
| Aug 20, 2025 | Nancy A Grygiel
Officer
|
Sell | 1.3K | $376.3K |
| Aug 8, 2025 | Michael V Drake
Director
|
Grant | 121 | - |
| Aug 8, 2025 | Charles M Holley Jr
Director
|
Grant | 147 | - |
| Aug 8, 2025 | Omar Syed Ishrak
Director
|
Grant | 121 | - |
| Jun 5, 2025 | Rachna Khosla
Officer
|
Sell | 1.5K | $434.5K |
| May 23, 2025 | Wanda M Austin
Director
|
Grant | 809 | - |
| May 23, 2025 | Michael V Drake
Director
|
Grant | 809 | - |
| May 23, 2025 | Brian J Druker
Director
|
Grant | 809 | - |
| May 23, 2025 | Robert Andrew Eckert
Director
|
Grant | 809 | - |
| May 23, 2025 | Gregory C. Garland
Director
|
Grant | 809 | - |
| May 23, 2025 | Charles M Holley Jr
Director
|
Grant | 809 | - |
| May 23, 2025 | Omar Syed Ishrak
Director
|
Grant | 809 | - |
| May 23, 2025 | Tyler Jacks
Director
|
Grant | 809 | - |
| May 23, 2025 | Mary E Klotman
Director
|
Grant | 809 | - |
| May 23, 2025 | Ellen Jamison Kullman
Director
|
Grant | 809 | - |
| May 23, 2025 | Amy E Miles
Director
|
Grant | 809 | - |
| May 6, 2025 | James E. Bradner
Officer
|
Grant | 3.5K | - |
| May 6, 2025 | Robert A Bradway
Chief Executive Officer
|
Grant | 13.3K | - |
| May 6, 2025 | Matthew C. Busch
Officer
|
Grant | 554 | - |
| May 6, 2025 | Michael V Drake
Director
|
Grant | 129 | - |
| May 6, 2025 | Murdo Gordon
Officer
|
Grant | 3.9K | - |
| May 6, 2025 | Jonathan P Graham
General Counsel
|
Grant | 3.2K | - |
| May 6, 2025 | Peter H. Griffith
Chief Financial Officer
|
Grant | 3.9K | - |
| May 6, 2025 | Nancy A Grygiel
Officer
|
Grant | 591 | - |
| May 6, 2025 | Charles M Holley Jr
Director
|
Grant | 157 | - |
| May 6, 2025 | Omar Syed Ishrak
Director
|
Grant | 129 | - |
| May 6, 2025 | Rachna Khosla
Officer
|
Grant | 610 | - |
| May 6, 2025 | Derek Miller
Officer
|
Grant | 961 | - |
| May 6, 2025 | David M. Reese
Chief Technology Officer
|
Grant | 3.5K | - |
| May 6, 2025 | Esteban Santos
Officer
|
Grant | 3.3K | - |
| May 2, 2025 | Matthew C. Busch
Officer
|
Sell | 1.0K | $279.7K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.